Is VEGF a predictive biomarker to anti-angiogenic therapy?
Crit Rev Oncol Hematol
; 79(2): 103-11, 2011 Aug.
Article
en En
| MEDLINE
| ID: mdl-20724177
ABSTRACT
Tumor growth and metastasis are dependent on angiogenesis. Inhibiting angiogenesis has therapeutic potentials for treating cancer. Researchers have identified many of the pathways involved in angiogenesis and proposed selective targeted strategies. A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to anti-angiogenic agents are inconclusive for predicting benefit from these drugs. This paper reviews the most important biomarker of angiogenesis, namely VEGF, in relation to its expression in cancer and the treatment of these cancers through targeting VEGF and its pathways.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores
/
Isoformas de Proteínas
/
Inhibidores de la Angiogénesis
/
Factores de Crecimiento Endotelial Vascular
/
Inhibidores de Proteínas Quinasas
/
Anticuerpos Monoclonales
/
Neoplasias
/
Neovascularización Patológica
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Crit Rev Oncol Hematol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
Año:
2011
Tipo del documento:
Article
País de afiliación:
Líbano